open access

Vol 6, No 2 (2003)
Published online: 2003-10-10
Submitted: 2012-01-23
Get Citation

Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma

Rafał Wiercioch, Ewa Balcerczak, Ewa Byszewska, Marek Mirowski
Nucl. Med. Rev 2003;6(2):99-103.

open access

Vol 6, No 2 (2003)
Published online: 2003-10-10
Submitted: 2012-01-23

Abstract

BACKGROUND: The aim of this study was to examine the biodistribution of 131I-herceptin in C3H/Bi mice with transplantable mammary adenocarcinoma with a high frequency of C-erbB2 receptor expression.
MATERIAL AND METHODS: Mice C3H/Bi with subcutaneously transplanted mammary adenocarcinoma were used as animal model to study the interaction between C-erbB2 receptor and hercepin, a humanized anti-C-erbB2 monoclonal antibody. The expression of the gene encoding C-erbB2 receptor in the tumours was studied by the RT-PCR technique.
RESULTS: Expression of this gene was found in 66% of the studied cases. Similarly, the presence of the C-erbB2 receptor in 77% of the tumours was detected by a Western blot analysis with the use of herceptin. Biodistribution experiments of iodine-labelled herceptin in mice C3H/Bi with adenocarcinoma revealed its maximal accumulation in the tumours at 48 hours since the i.v. injection (7% ID/g). The tumour/muscle radioactivity ratio reached its highest value (above 20) also at 48 hours after the injection.
CONCLUSIONS: C3H/Bi mice with this adenocarcinoma may be a good experimental model to study herceptin, or its fragments, labelled with different radionuclids for preliminary evaluation of their usefulness in the therapeutic and diagnostic aspects of breast cancer.

Abstract

BACKGROUND: The aim of this study was to examine the biodistribution of 131I-herceptin in C3H/Bi mice with transplantable mammary adenocarcinoma with a high frequency of C-erbB2 receptor expression.
MATERIAL AND METHODS: Mice C3H/Bi with subcutaneously transplanted mammary adenocarcinoma were used as animal model to study the interaction between C-erbB2 receptor and hercepin, a humanized anti-C-erbB2 monoclonal antibody. The expression of the gene encoding C-erbB2 receptor in the tumours was studied by the RT-PCR technique.
RESULTS: Expression of this gene was found in 66% of the studied cases. Similarly, the presence of the C-erbB2 receptor in 77% of the tumours was detected by a Western blot analysis with the use of herceptin. Biodistribution experiments of iodine-labelled herceptin in mice C3H/Bi with adenocarcinoma revealed its maximal accumulation in the tumours at 48 hours since the i.v. injection (7% ID/g). The tumour/muscle radioactivity ratio reached its highest value (above 20) also at 48 hours after the injection.
CONCLUSIONS: C3H/Bi mice with this adenocarcinoma may be a good experimental model to study herceptin, or its fragments, labelled with different radionuclids for preliminary evaluation of their usefulness in the therapeutic and diagnostic aspects of breast cancer.
Get Citation

Keywords

herceptin; C-erbB2; receptor binding; breast cancer

About this article
Title

Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma

Journal

Nuclear Medicine Review

Issue

Vol 6, No 2 (2003)

Pages

99-103

Published online

2003-10-10

Bibliographic record

Nucl. Med. Rev 2003;6(2):99-103.

Keywords

herceptin
C-erbB2
receptor binding
breast cancer

Authors

Rafał Wiercioch
Ewa Balcerczak
Ewa Byszewska
Marek Mirowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl